Rheumatoid Arthritis - Genmab Reports ACR50 And ACR70 Results In HuMax-CD20 Study

... Genmab A/S(CSE: GEN) announced today additional data from the HuMax-CD20(TM) Phase I/IIstudy to treat patients with active rheumatoid arthritis (RA). In patientswho received two doses of HuMax-CD20, 38% (10/26) achieved ACR50 and 15%(4/26) achieved ACR70. There were three dose levels in the study with results as follows: ------- In the 300 mg dose group -- 25% (2/8) of patients achieved ACR50 -- 13% (1/8) achieved ACR70 ------- In the 700 mg dose group -- 44% (4/9) achieved ACR50 -- 22% (2/9) achieved ACR70 ------- In the 1000 mg dose group -- 44% (4/9) achieved ACR50 -- 11% (1/9) achieved ACR70 After re-examination of the previously reported ACR20 data, it appears oneof the responders in the 300 mg dose group had received only one dose ofHuMax-CD20, thus 73% (19/26) of patients treated with two doses of HuMax-CD20achieved ACR20... click link for more info. ...